Bongiolatti Stefano, Voltolini Luca, Borgianni Sara, Borrelli Roberto, Innocenti Marco, Menichini Giulio, Politi Leonardo, Tancredi Giorgia, Viggiano Domenico, Gonfiotti Alessandro
Thoracic Surgery Unit, Careggi University Hospital, Florence, Italy.
Plastic Surgery Unit, Careggi University Hospital, Florence, Italy.
J Thorac Dis. 2017 Nov;9(11):4336-4346. doi: 10.21037/jtd.2017.10.94.
We analyzed our experience in sternal resections (SRs) for primary or secondary neoplasm focusing on technical aspects of reconstruction, post-operative outcomes and long term survival.
From January 2005 to December 2015, 36 patients (24 males, 67%) underwent surgical excision of primary (chondrosarcoma n=18 patients, 50%; osteosarcoma n=2, 6%; Ewing sarcoma n=1, 3%; other n=2, 6%) or secondary (breast cancer n=7, 19%; kidney carcinoma n=2, 6%) sternal tumour. We performed n=30 partial sternectomy and n=6 total sternectomy with en-bloc resection of the sternocostal cartilages in all patient and extended resection in 7 patients. Stability was obtained with prosthetic material, rigid and non-rigid and a muscular flap: rigid material [Strasbourg Thoracic Osteosynthesis System (STRATOS), MedXpert GmbH] and muscle flap n=11 (30.6%); polytetrafluoroethylene patch and muscle flap n=6 (16.7%); muscle flap alone n=19 (52.8%).
The 30-day mortality rate was 0, overall complication rate was 19%. The median ICU stay was 1.5 days and mean hospital stay was 10.6±5.9 days. We obtained a complete (R0) resection in all patients. Overall survival (OS) at 5 and 10 years were 59% and 40%; in the group of primary neoplasm OS rate at 5 and 10 years was 79% and 54%. Disease free survival (DFS) rate at 5 years was 61%. Higher grading was identified as negative prognostic factor.
Wide radical resections of anterior chest wall are basilar in a multimodality treatment for primary or metastatic neoplasm of the sternum. Stabilization with titanium bars and clips provides rigidity of chest wall with good functional results.
我们分析了我们在因原发性或继发性肿瘤行胸骨切除术(SRs)方面的经验,重点关注重建的技术方面、术后结果和长期生存情况。
2005年1月至2015年12月,36例患者(24例男性,67%)接受了原发性(软骨肉瘤n = 18例,50%;骨肉瘤n = 2例,6%;尤因肉瘤n = 1例,3%;其他n = 2例,6%)或继发性(乳腺癌n = 7例,19%;肾癌n = 2例,6%)胸骨肿瘤的手术切除。所有患者均行n = 30例部分胸骨切除术和n = 6例全胸骨切除术,并整块切除胸骨肋软骨,7例患者行扩大切除术。采用假体材料、刚性和非刚性材料以及肌瓣实现稳定性:刚性材料[斯特拉斯堡胸廓骨合成系统(STRATOS),MedXpert GmbH]和肌瓣n = 11例(30.6%);聚四氟乙烯补片和肌瓣n = 6例(16.7%);单纯肌瓣n = 19例(52.8%)。
30天死亡率为0,总体并发症发生率为19%。ICU中位住院时间为1.5天,平均住院时间为10.6±5.9天。所有患者均实现了根治性(R0)切除。5年和10年的总生存率(OS)分别为59%和40%;原发性肿瘤组5年和10年的OS率分别为79%和54%。5年无病生存率(DFS)为61%。分级较高被确定为不良预后因素。
在前胸壁广泛根治性切除是胸骨原发性或转移性肿瘤多模式治疗的基础。钛棒和钛夹固定可提供胸壁刚性,功能效果良好。